Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Silmitasertib - Senhwa Biosciences

Next Previous
Drug Profile

Silmitasertib - Senhwa Biosciences

Alternative Names: CX 4945

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cylene Pharmaceuticals
  • Developer Cylene Pharmaceuticals; Penn State College of Medicine; Senhwa Biosciences; Stanford University School of Medicine
  • Class 3-ring heterocyclic compounds; Antineoplastics; Antivirals; Carboxylic acids; Naphthyridines; Small molecules
  • Mechanism of Action Casein kinase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer; Cholangiocarcinoma; Medulloblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia; COVID 2019 infections
  • Phase I/II Cholangiocarcinoma; Medulloblastoma; Solid tumours
  • Preclinical Acute myeloid leukaemia; HIV infections; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • No development reported Basal cell cancer; Giant lymph node hyperplasia; Multiple myeloma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Aug 2025 No recent reports of development identified for phase-I development in Basal-cell-cancer(Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 28 Aug 2025 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in Taiwan
  • 25 Jun 2025 Preclinical trials in HIV infections in China (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top